Fabre A, Fournier A, Mesrine S, Desreux J, Gompel A, Boutron-Ruault M-C, Clavel-Chapelon F
Institut National de la Santé et de la Recherche Médicale, ERI 20, Institut Gustave Roussy, 39, rue Camille Desmoulins, F-94805 Villejuif, Cedex, France.
Br J Cancer. 2007 Mar 12;96(5):841-4. doi: 10.1038/sj.bjc.6603618. Epub 2007 Feb 13.
We examined the relationship between use of progestagen-only before menopause (except for mini-pills) after the age of 40 and invasive breast cancer risk in 73 664 women from the French E3N cohort study (mean age at start of follow-up, 51.8 years; mean duration of follow-up, 9.1 years). A total of 2390 cases of invasive breast cancer were diagnosed during follow-up. Risk estimates were calculated using the Cox proportional hazard model. Overall, ever use of progestagen before menopause was not significantly associated with risk (relative risk (RR): 1.01, 95% confidence interval: 0.93-1.11). However, we observed a significant increase in risk associated with the duration of use (P-value for trend: 0.012), current use of progestagens for longer than 4.5 years being significantly associated with risk (RR: 1.44, 95% confidence interval: 1.03-2.00). Prolonged use of progestagens after the age of 40 may be associated with an increased risk of breast cancer and the subject needs to be investigated further.
我们在法国E3N队列研究的73664名女性中（随访开始时的平均年龄为51.8岁；平均随访时间为9.1年），研究了40岁后绝经前（不包括短效口服避孕药）使用单纯孕激素与浸润性乳腺癌风险之间的关系。随访期间共诊断出2390例浸润性乳腺癌病例。风险估计采用Cox比例风险模型计算。总体而言，绝经前曾使用孕激素与风险无显著关联（相对风险（RR）：1.01，95%置信区间：0.93 - 1.11）。然而，我们观察到风险随使用时间的延长而显著增加（趋势P值：0.012），当前使用孕激素超过4.5年与风险显著相关（RR：1.44，95%置信区间：1.03 - 2.00）。40岁后长期使用孕激素可能与乳腺癌风险增加有关，该问题需要进一步研究。
